Company intelligence / Profile preview

Keystone Heart

Caesarea, Israel

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Keystone Heart is a medical device company focused on developing and manufacturing cerebral embolic protection devices for patients undergoing structural heart procedures. Its flagship product, the TriGuard 3, is designed to cover all three major cerebral arteries to minimize the risk of brain damage by filtering and deflecting debris during procedures such as Transcatheter Aortic Valve Replacement (TAVR). The company aims to reduce the incidence of stroke and neurocognitive decline associated with cardiovascular interventions. Headquartered in Israel with a significant US presence, Keystone Heart was acquired by Venus Medtech in 2018 to bolster their structural heart portfolio.

Therapeutic areas: CardiovascularNeurology
Modalities: Device
Industry: Surgical Medical Devices

Partnerships

Venus Medtech

Beyond the preview

Go deeper on Keystone Heart.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Keystone Heart.

Explore the full profile